Ian Geoffrey Mills

Mitochondrial metabolism is a key determinant of chemotherapy sensitivity in Colorectal Cancer

This study identifies mitochondrial metabolism as a key factor in 5-fluorouracil resistance in colorectal cancer and shows that targeting mitochondrial Complex I can enhance chemotherapy effectiveness.

3D pathology-guided microdissection

This paper introduces a 3D microdissection method combining CNC milling and light-sheet microscopy to study tumor evolution in complex 3D structures.

Assessing the effects of a 3D pathology tissue-processing workflow on downstream molecular analyses

This study evaluates the impact of a 3D pathology workflow on DNA, RNA, and protein integrity, showing minimal effect on amplifiability and transcriptomic profiles.

Germline polygenic score for prostate cancer aggressiveness

This paper develops a germline polygenic score (PRSagg) to predict prostate cancer aggressiveness and validates it across multiple datasets.

NNMT drives innate sensitivity to NAMPT inhibition in YAP-dependent stem-like/ mesenchymal prostate cancer

This study identifies the YAP/NNMT axis as a driver of innate sensitivity to NAMPT inhibition in stem-like mesenchymal prostate cancer, suggesting NNMT as a biomarker for NAD+-targeting therapies.

IGFs regulate cancer cell immune evasion in prostate cancer

This study shows IGF-1 suppresses immune-related pathways in prostate cancer cells, reducing antigen presentation and increasing PD-L1, which may explain poor immunotherapy response.

IRE1 activity regulates tumour and microenvironment cell lineage states while stratifying localised and metastatic prostate cancer.

This paper identifies IRE1 activity as a regulator of prostate cancer cell lineage states and shows its role in predicting prognosis and treatment response across localized and metastatic disease.

From a genomic risk model to clinical trial implementation in a learning health system: the ProGRESS Study

The paper develops a polygenic risk model for prostate cancer using VA data and validates it in external cohorts, showing its clinical utility in risk stratification.

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease.

Clonal phylogenies inferred from bulk, single cell, and spatial transcriptomic analysis of cancer

The paper evaluates the accuracy of transcript-based inferred tumor phylogenies compared to DNA-based phylogenies in prostate cancer using single-cell, spatial transcriptomic, and bulk data.

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of heterogeneity on genomic signature scoring

The paper uses spatial transcriptomic data to show that bulk genomic signature scoring in prostate cancer biopsies is confounded by tumour heterogeneity, leading to inaccurate risk assessments.

Prostate cancer risk stratification improved across multiple ancestries with new polygenic hazard score

The paper improves prostate cancer risk stratification across multiple ancestries using a new polygenic hazard score with additional SNPs, showing higher hazard ratios and positive predictive value for clinically significant prostate cancer.

The spatial landscape of clonal somatic mutations in benign and malignant tissue

The paper uses spatial transcriptomics to analyze copy number variations in benign and malignant tissues, revealing clonal patterns and suggesting early cancer evolution mechanisms.

Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24

The paper assesses how the performance of an African-ancestry-specific polygenic hazard score varies with local ancestry in 8q24 using genetic data from 6,253 men with African ancestry.

Common genetic and clinical risk factors: Association with fatal prostate cancer in the Cohort of Swedish Men

This study evaluates if adding polygenic hazard scores to clinical variables improves association with fatal prostate cancer in the Cohort of Swedish Men.

Polygenic hazard score is associated with prostate cancer in multi-ethnic populations

This study evaluates a polygenic hazard score in multi-ethnic populations and finds it is associated with age at prostate cancer diagnosis, aggressive diagnosis, and death across European, Asian, and African ancestries.

Additional SNPs improve the performance of a polygenic hazard score for prostate cancer

This study improves a polygenic hazard score for prostate cancer by adding 120 SNPs, enhancing hazard ratios but not positive predictive value of PSA testing.

African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer

The paper improves a polygenic hazard score for prostate cancer age at diagnosis by adding SNPs specific to African ancestry, enhancing performance in this population.

The effect of sample size on polygenic hazard models for prostate cancer

This paper evaluates how sample size affects polygenic hazard score models for prostate cancer, finding that 20-30k samples are needed for discovery models, but 10k suffice if SNPs are pre-established.

High-throughput propagation of human prostate tissue from induced-pluripotent stem cells

This paper introduces a high-throughput method to generate human prostate tissue from induced pluripotent stem cells using co-culture with urogenital sinus mesenchyme.

A genetic hazard score to personalize prostate cancer screening, applied to population data

The paper evaluates a polygenic hazard score for prostate cancer screening, showing it improves positive predictive value by adjusting screening age based on genetic risk.

A genetic risk score to guide age-specific, personalized prostate cancer screening

This paper develops a genetic risk score to personalize prostate cancer screening age based on polygenic hazard scores and validates its predictive power in a separate dataset.